Clinical Trial Update: A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 study evaluating safety and activity of nivolumab with daratumumab in patients with pancreatic cancer, non-small cell lung cancer, or triple-negativ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Pancreatic Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Daratumumab (daratumumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Advanced Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-07-23